Evidence map›Paper›PMID 42481797›Full record

ArticleLeukemia2026

Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.

Estefania Gauto Mariotti, Shaji Kumar, Wilson Gonsalves, Prashant Kapoor, Francis Buadi, Suzanne Hayman, Nadine Abdallah, Moritz Binder, Joselle Cook, Angela Dispenzieri and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Estefania Gauto MariottiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5710-4714
Shaji KumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.ORCID http://orcid.org/0000-0001-5392-9284
Wilson GonsalvesDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-6890-969X
Prashant KapoorDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4342-364X
Francis BuadiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-3214-0203
Suzanne HaymanDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Nadine AbdallahDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-9195-1589
Moritz BinderDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-9014-9658
Joselle CookDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5335-9533
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8780-9512
David DingliDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7477-3004
Morie A GertzDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3853-5196
Taxiarchis KourelisDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8573-9434
Nelson LeungDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5651-1411
Yi LinDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1556-6416
Mustaqeem SiddiquiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Ronald GoDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-8284-3495
Eli MuchtarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2210-2174
Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Dragan JevremovicDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1792-5822
Robert A KyleDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
S Vincent RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5862-1833
Saurabh ZanwarDivision of Hematology, Mayo Clinic, Rochester, MN, USA. zanwar.saurabh@mayo.edu.ORCID http://orcid.org/0000-0001-5074-8453

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurable residual disease (MRD) assessment has become central to risk-adapted treatment strategies in multiple myeloma, yet the prognostic value of MRD negativity following autologous stem cell transplantation (ASCT) across individual high-risk cytogenetic abnormalities (HRCAs) remains unclear. We analyzed 351 newly diagnosed patients who achieved MRD negativity (sensitivity 2.4 × 10

Indexed as

Chromosome AberrationsHematopoietic Stem Cell TransplantationMultiple MyelomaNeoplasm, ResidualAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisTransplantation, Autologous

Identifiers

PMID42481797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.